Agenus Stock Price, News & Analysis (NASDAQ:AGEN)

$4.35 +0.14 (+3.33 %)
(As of 02/20/2018 10:30 AM ET)
Previous Close$4.35
Today's Range$4.03 - $4.37
52-Week Range$3.20 - $5.45
Volume2.25 million shs
Average Volume1.33 million shs
Market Capitalization$464.75 million
P/E Ratio-3.97
Dividend YieldN/A
Beta2.1

About Agenus (NASDAQ:AGEN)

Agenus logoAgenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:AGEN
CUSIP00847G70
Phone+1-781-6744410

Debt

Debt-to-Equity Ratio-2.39%
Current Ratio1.55%
Quick Ratio1.55%

Price-To-Earnings

Trailing P/E Ratio-3.96581196581197
Forward P/E Ratio-3.75
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.57 million
Price / Sales19.65
Cash FlowN/A
Price / CashN/A
Book Value($0.45) per share
Price / Book-9.67

Profitability

Trailing EPS($1.17)
Net Income$-126,990,000.00
Net Margins-278.76%
Return on EquityN/A
Return on Assets-65.18%

Miscellaneous

Employees255
Outstanding Shares101,960,000

Agenus (NASDAQ:AGEN) Frequently Asked Questions

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus Inc (NASDAQ:AGEN) announced its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.37). The biotechnology company had revenue of $3.40 million for the quarter, compared to analysts' expectations of $5.91 million. Agenus's revenue for the quarter was down 24.4% compared to the same quarter last year. View Agenus' Earnings History.

When will Agenus make its next earnings announcement?

Agenus is scheduled to release their next quarterly earnings announcement on Thursday, March, 8th 2018. View Earnings Estimates for Agenus.

Where is Agenus' stock going? Where will Agenus' stock price be in 2018?

3 brokerages have issued 1-year price targets for Agenus' stock. Their predictions range from $5.00 to $7.00. On average, they anticipate Agenus' stock price to reach $6.33 in the next year. View Analyst Ratings for Agenus.

Are investors shorting Agenus?

Agenus saw a decrease in short interest during the month of January. As of January 12th, there was short interest totalling 9,254,236 shares, a decrease of 9.3% from the December 29th total of 10,204,389 shares. Based on an average daily trading volume, of 1,432,591 shares, the short-interest ratio is presently 6.5 days. Approximately 12.0% of the company's stock are short sold.

Who are some of Agenus' key competitors?

Who are Agenus' key executives?

Agenus' management team includes the folowing people:

  • Garo H. Armen Ph.D., Chairman of the Board, Chief Executive Officer, Founder (Age 64)
  • Christine M. Klaskin, Vice President - Finance (Age 51)
  • Karen Higgins Valentine, General Counsel, Chief Legal Officer (Age 45)
  • Ozer Baysal, Chief Commercial Officer, Head of HR (Age 61)
  • Brian Corvese, Independent Director (Age 59)
  • Wadih Jordan, Independent Director (Age 82)
  • Shalini Sharp, Independent Director (Age 42)
  • Ulf Wiinberg, Independent Director (Age 58)
  • Timothy R. Wright, Independent Director (Age 59)

Who owns Agenus stock?

Agenus' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.79%), RTW Investments LP (4.25%), QVT Financial LP (3.14%), Millennium Management LLC (2.44%), Candriam Luxembourg S.C.A. (0.64%) and Hudson Bay Capital Management LP (0.44%). Company insiders that own Agenus stock include Alex Duncan, Christine M Klaskin, Corp Incyte, Garo H Armen, Karen Valentine, Ozer Baysal and Ulf Wiinberg. View Institutional Ownership Trends for Agenus.

Who sold Agenus stock? Who is selling Agenus stock?

Agenus' stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Goldman Sachs Group Inc., QVT Financial LP, Wells Fargo & Company MN, TIAA CREF Investment Management LLC, Alliancebernstein L.P. and Rhumbline Advisers. Company insiders that have sold Agenus company stock in the last year include Alex Duncan, Christine M Klaskin and Karen Valentine. View Insider Buying and Selling for Agenus.

Who bought Agenus stock? Who is buying Agenus stock?

Agenus' stock was purchased by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, RTW Investments LP, Virtus Fund Advisers LLC, Deutsche Bank AG, North Star Asset Management Inc., Fisher Asset Management LLC, BlackRock Inc. and Raymond James & Associates. Company insiders that have bought Agenus stock in the last two years include Corp Incyte, Garo H Armen, Ozer Baysal and Ulf Wiinberg. View Insider Buying and Selling for Agenus.

How do I buy Agenus stock?

Shares of Agenus can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of Agenus stock can currently be purchased for approximately $4.35.

How big of a company is Agenus?

Agenus has a market capitalization of $464.75 million and generates $22.57 million in revenue each year. The biotechnology company earns $-126,990,000.00 in net income (profit) each year or ($1.17) on an earnings per share basis. Agenus employs 255 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 Forbes Rd, LEXINGTON, MA 02421-7305, United States. The biotechnology company can be reached via phone at +1-781-6744410 or via email at [email protected]


MarketBeat Community Rating for Agenus (AGEN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  255 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Agenus (NASDAQ:AGEN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.672.752.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.33$6.33$6.33$6.33
Price Target Upside: 57.55% upside57.55% upside57.55% upside57.55% upside

Agenus (NASDAQ:AGEN) Consensus Price Target History

Price Target History for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2017Jefferies GroupReiterated RatingBuy$7.00HighView Rating Details
5/6/2017HC WainwrightSet Price TargetHold$5.00LowView Rating Details
4/23/2017Maxim GroupReiterated RatingBuy$7.00MediumView Rating Details
12/1/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$17.00 -> $15.00N/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

Agenus (NASDAQ:AGEN) Earnings History and Estimates Chart

Earnings by Quarter for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ AGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/8/2018        
11/7/2017Q3($0.37)($0.37)$5.91 million$3.40 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.36)($0.32)$6.66 million$4.21 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.32)($0.18)$5.22 million$26.96 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.30)($0.30)$6.01 million$5.58 millionViewListenView Earnings Details
10/27/2016Q316($0.32)($0.47)$6.15 million$4.45 millionViewListenView Earnings Details
7/28/2016Q216($0.34)($0.33)$5.12 million$6.59 millionViewListenView Earnings Details
4/28/2016Q116($0.23)($0.37)$6.74 million$5.96 millionViewListenView Earnings Details
3/3/2016Q415($0.17)($0.18)$9.39 million$7.64 millionViewListenView Earnings Details
10/27/2015Q315($0.15)($0.16)$5.71 million$6.85 millionViewListenView Earnings Details
7/23/2015Q215($0.15)($0.44)$5.71 million$6.38 millionViewListenView Earnings Details
4/23/2015Q115($0.15)($0.21)$11.66 million$3.95 millionViewN/AView Earnings Details
2/26/2015Q414($0.15)($0.18)$0.66 million$1.62 millionViewN/AView Earnings Details
10/31/2014Q314($0.15)($0.13)$1.96 million$1.56 millionViewN/AView Earnings Details
7/24/2014Q214($0.11)($0.12)$0.71 million$3.07 millionViewN/AView Earnings Details
5/8/2014Q114($0.16)$0.01$0.55 million$0.72 millionViewN/AView Earnings Details
3/5/2014Q413($0.24)($0.16)$870.00 million$393.00 millionViewN/AView Earnings Details
10/24/2013Q313($0.27)($0.24)$736.00 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.21)($0.40)$1.18 million$0.81 millionViewN/AView Earnings Details
4/24/2013Q1 2013($0.19)($0.35)$1.13 million$1.11 millionViewN/AView Earnings Details
2/28/2013Q4 2012($0.24)($0.23)$0.72 million$1.09 millionViewN/AView Earnings Details
10/25/2012Q3 2012($0.28)($0.24)ViewN/AView Earnings Details
8/2/2012Q2 2012($0.26)($0.31)ViewN/AView Earnings Details
4/25/2012Q1 2012($0.29)$0.29ViewN/AView Earnings Details
3/5/2012Q4 2011($0.28)($0.29)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.27)($0.28)ViewN/AView Earnings Details
7/28/2011($0.05)($0.05)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.24)($0.30)ViewN/AView Earnings Details
2/17/2011Q4 2010($0.30)($0.18)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.36)($0.36)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.30)($0.32)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.36)($0.59)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.54)$0.11ViewN/AView Earnings Details
10/29/2009Q3 2009($0.66)($0.76)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.78)($1.02)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.72)($0.87)ViewN/AView Earnings Details
2/19/2009Q4 2008($0.96)($0.65)ViewN/AView Earnings Details
11/5/2008Q3 2008($1.08)($1.01)ViewN/AView Earnings Details
7/31/2008Q2 2008($1.08)($1.13)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.84)($1.21)ViewN/AView Earnings Details
2/21/2008Q4 2007($1.38)($0.97)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Agenus (NASDAQ:AGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.36)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.35)($0.35)($0.35)
Q2 20181($0.34)($0.34)($0.34)
Q3 20181($0.33)($0.33)($0.33)
Q4 20181($0.34)($0.34)($0.34)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Agenus (NASDAQ:AGEN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Agenus (NASDAQ AGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 37.44%
Insider Trades by Quarter for Agenus (NASDAQ:AGEN)
Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ AGEN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/12/2017Alex DuncanCTOSell6,546$3.46$22,649.1627,572View SEC Filing  
12/12/2017Christine M KlaskinVPSell5,610$3.46$19,410.6069,943View SEC Filing  
12/12/2017Karen ValentineInsiderSell8,358$3.46$28,918.68109,879View SEC Filing  
10/30/2017Garo H ArmenCEOBuy100,000$3.55$355,000.00View SEC Filing  
4/12/2017Garo H ArmenCEOBuy100,000$3.35$335,000.001,389,021View SEC Filing  
2/14/2017Corp IncyteMajor ShareholderBuy10,000,000$6.00$60,000,000.0017,763,968View SEC Filing  
9/6/2016Ulf WiinbergDirectorBuy30,000$6.29$188,700.0030,000View SEC Filing  
5/9/2016Garo H ArmenCEOBuy100,000$3.18$318,000.001,346,026View SEC Filing  
5/5/2016Ozer BaysalInsiderBuy2,250$3.10$6,975.0033,538View SEC Filing  
3/7/2016Garo H ArmenCEOBuy200,000$4.03$806,000.001,251,228View SEC Filing  
12/29/2015Garo H. ArmenCEOSell219,576$4.59$1,007,853.841,051,228View SEC Filing  
12/28/2015Garo H. ArmenCEOSell134,352$4.60$618,019.201,051,228View SEC Filing  
9/25/2015Charles Evan BallantyneCFOBuy10,000$5.05$50,500.0010,000View SEC Filing  
9/25/2015Garo H ArmenCEOBuy100,000$5.03$503,000.001,409,607View SEC Filing  
4/29/2015Shahzad MalikDirectorSell1,107,377$7.11$7,873,450.47View SEC Filing  
1/9/2015Qvt Associates Gp LlcMajor ShareholderSell2,343,630$5.31$12,444,675.30View SEC Filing  
1/23/2014Karen ValentineVPSell2,850$3.50$9,975.0051,534View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Agenus (NASDAQ AGEN) News Headlines

Source:
DateHeadline
Agenus: Positioned To Rapidly Enhance Shareholder ValueAgenus: Positioned To Rapidly Enhance Shareholder Value
seekingalpha.com - February 20 at 8:42 AM
Agenus Inc (AGEN) Receives Consensus Recommendation of "Hold" from AnalystsAgenus Inc (AGEN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 20 at 1:36 AM
Agenus (AGEN) Upgraded by BidaskClub to HoldAgenus (AGEN) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - February 17 at 1:40 PM
Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock?
www.msn.com - February 13 at 9:39 AM
Is Agenus Inc. a Buy?Is Agenus Inc. a Buy?
www.fool.com - February 13 at 8:16 AM
Agenus (AGEN) Raised to "Sell" at BidaskClubAgenus (AGEN) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - February 11 at 8:54 AM
Zacks: Brokerages Expect Agenus Inc (AGEN) Will Announce Quarterly Sales of $15.58 MillionZacks: Brokerages Expect Agenus Inc (AGEN) Will Announce Quarterly Sales of $15.58 Million
www.americanbankingnews.com - February 11 at 4:16 AM
Short Interest in Agenus Inc (AGEN) Drops By 9.3%Short Interest in Agenus Inc (AGEN) Drops By 9.3%
www.americanbankingnews.com - January 28 at 1:26 AM
Agenus Inc (AGEN) Given Average Rating of "Hold" by AnalystsAgenus Inc (AGEN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 26 at 1:24 AM
Zacks: Analysts Anticipate Agenus Inc (AGEN) Will Announce Quarterly Sales of $15.58 MillionZacks: Analysts Anticipate Agenus Inc (AGEN) Will Announce Quarterly Sales of $15.58 Million
www.americanbankingnews.com - January 25 at 2:32 AM
BRIEF-Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1BRIEF-Agenus Announces Combination Clinical Trials Of Anti-CTLA4 & Anti-PD1
www.reuters.com - January 23 at 3:43 PM
Agenus Announces Combination Clinical Trials of its Anti-CTLA4 ... - PR Newswire (press release)Agenus Announces Combination Clinical Trials of its Anti-CTLA4 ... - PR Newswire (press release)
www.prnewswire.com - January 22 at 1:31 PM
Agenus Inc. Closes $230 Million Royalty Monetization with ... - PR Newswire (press release)Agenus Inc. Closes $230 Million Royalty Monetization with ... - PR Newswire (press release)
www.prnewswire.com - January 22 at 1:31 PM
Agenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty PartnersAgenus Inc. Closes $230 Million Royalty Monetization with HealthCare Royalty Partners
finance.yahoo.com - January 22 at 1:31 PM
Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)Agenus Announces Combination Clinical Trials of its Anti-CTLA4 (AGEN1884) & Anti-PD1 (AGEN2034)
finance.yahoo.com - January 22 at 1:31 PM
Spectrum Pharmaceuticals Up 134% in 6 Months: Heres WhySpectrum Pharmaceuticals Up 134% in 6 Months: Here's Why
www.msn.com - January 19 at 11:54 AM
Will 2018 Be Agenus Inc.s Best Year Yet? - Motley FoolWill 2018 Be Agenus Inc.'s Best Year Yet? - Motley Fool
www.fool.com - January 17 at 3:29 PM
Will 2018 Be Agenus Inc.s Best Year Yet?Will 2018 Be Agenus Inc.'s Best Year Yet?
finance.yahoo.com - January 16 at 10:45 AM
Agenus (AGEN) Lowered to "Hold" at Zacks Investment ResearchAgenus (AGEN) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 5:14 PM
Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners - PR Newswire (press release)Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners - PR Newswire (press release)
www.prnewswire.com - January 10 at 10:28 AM
 Brokerages Anticipate Agenus Inc (AGEN) Will Post Quarterly Sales of $15.58 Million Brokerages Anticipate Agenus Inc (AGEN) Will Post Quarterly Sales of $15.58 Million
www.americanbankingnews.com - January 8 at 4:02 PM
Agenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty PartnersAgenus Inc. Announces $230 Million Royalty Monetization with HealthCare Royalty Partners
finance.yahoo.com - January 8 at 11:03 AM
Eiger Biopharmaceuticals (EIGR) and Agenus (AGEN) Financial ReviewEiger Biopharmaceuticals (EIGR) and Agenus (AGEN) Financial Review
www.americanbankingnews.com - January 6 at 7:14 PM
Technical Perspectives on Agenus, Coherus Biosciences, Global Blood Therapeutics, and Intercept Pharma - PR Newswire (press release)Technical Perspectives on Agenus, Coherus Biosciences, Global Blood Therapeutics, and Intercept Pharma - PR Newswire (press release)
www.prnewswire.com - January 6 at 3:29 PM
Why Agenus Inc. Stock Sank in December -- The Motley Fool - Motley FoolWhy Agenus Inc. Stock Sank in December -- The Motley Fool - Motley Fool
www.fool.com - January 6 at 3:29 PM
-$0.28 EPS Expected for Agenus Inc (AGEN) This Quarter-$0.28 EPS Expected for Agenus Inc (AGEN) This Quarter
www.americanbankingnews.com - January 6 at 11:26 AM
Why Agenus Inc. Stock Sank in DecemberWhy Agenus Inc. Stock Sank in December
www.fool.com - January 6 at 8:39 AM
Agenus Dr. John Castle Joins Thought Leadership Panel on IO Combinations at 10th Annual Biotech Showcase 2018 - PR Newswire (press release)Agenus' Dr. John Castle Joins Thought Leadership Panel on IO Combinations at 10th Annual Biotech Showcase 2018 - PR Newswire (press release)
www.prnewswire.com - January 4 at 3:28 PM
Agenus Announces Key Leadership to Advance Combination Trials ... - PR Newswire (press release)Agenus Announces Key Leadership to Advance Combination Trials ... - PR Newswire (press release)
www.prnewswire.com - January 4 at 3:28 PM
Agenus Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018Agenus' Dr. John Castle Joins Thought Leadership Panel on I-O Combinations at 10th Annual Biotech Showcase 2018
finance.yahoo.com - January 4 at 9:37 AM
Agenus Announces Key Leadership to Advance Combination Trials For Planned BLA FilingsAgenus Announces Key Leadership to Advance Combination Trials For Planned BLA Filings
finance.yahoo.com - January 3 at 11:01 AM
ETFs with exposure to Agenus, Inc. : January 2, 2018ETFs with exposure to Agenus, Inc. : January 2, 2018
finance.yahoo.com - January 2 at 3:38 PM
Agenus Inc (AGEN) Given Consensus Recommendation of "Hold" by BrokeragesAgenus Inc (AGEN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 1 at 1:56 AM
Agenus (AGEN) Downgraded by ValuEngineAgenus (AGEN) Downgraded by ValuEngine
www.americanbankingnews.com - December 29 at 5:48 PM
Agenus (AGEN) & Its Competitors Head-To-Head ReviewAgenus (AGEN) & Its Competitors Head-To-Head Review
www.americanbankingnews.com - December 28 at 7:34 PM
Jefferies Group Comments on Agenus Incs FY2017 Earnings (AGEN)Jefferies Group Comments on Agenus Inc's FY2017 Earnings (AGEN)
www.americanbankingnews.com - December 25 at 3:30 AM
 Analysts Anticipate Agenus Inc (AGEN) Will Post Quarterly Sales of $15.58 Million Analysts Anticipate Agenus Inc (AGEN) Will Post Quarterly Sales of $15.58 Million
www.americanbankingnews.com - December 23 at 11:18 AM
ETFs with exposure to Agenus, Inc. : December 22, 2017ETFs with exposure to Agenus, Inc. : December 22, 2017
finance.yahoo.com - December 22 at 3:55 PM
Agenus (AGEN) & Its Peers Financial AnalysisAgenus (AGEN) & Its Peers Financial Analysis
www.americanbankingnews.com - December 21 at 11:24 AM
 Analysts Anticipate Agenus Inc (AGEN) Will Announce Earnings of -$0.37 Per Share Analysts Anticipate Agenus Inc (AGEN) Will Announce Earnings of -$0.37 Per Share
www.americanbankingnews.com - December 21 at 1:14 AM
Analyzing Agenus (AGEN) & Its CompetitorsAnalyzing Agenus (AGEN) & Its Competitors
www.americanbankingnews.com - December 20 at 1:20 PM
Agenus (AGEN) versus Abeona Therapeutics (ABEO) Head-To-Head ContrastAgenus (AGEN) versus Abeona Therapeutics (ABEO) Head-To-Head Contrast
www.americanbankingnews.com - December 19 at 3:16 AM
Agenus Inc. (AGEN) Insider Karen Valentine Sells 8,358 SharesAgenus Inc. (AGEN) Insider Karen Valentine Sells 8,358 Shares
www.americanbankingnews.com - December 14 at 6:50 PM
Agenus Inc. (AGEN) CTO Alex Duncan Sells 6,546 SharesAgenus Inc. (AGEN) CTO Alex Duncan Sells 6,546 Shares
www.americanbankingnews.com - December 14 at 6:50 PM
Christine M. Klaskin Sells 5,610 Shares of Agenus Inc. (AGEN) StockChristine M. Klaskin Sells 5,610 Shares of Agenus Inc. (AGEN) Stock
www.americanbankingnews.com - December 14 at 6:50 PM
Agenus (AGEN) vs. Its Peers Critical ContrastAgenus (AGEN) vs. Its Peers Critical Contrast
www.americanbankingnews.com - December 11 at 3:34 PM
ETFs with exposure to Agenus, Inc. : December 11, 2017ETFs with exposure to Agenus, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 3:27 PM
Agenus (AGEN) Rating Lowered to Sell at BidaskClubAgenus (AGEN) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - December 9 at 10:36 AM
Agenus Inc. (AGEN) Receives Consensus Rating of "Hold" from BrokeragesAgenus Inc. (AGEN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - December 7 at 1:46 AM
Agenus Inc. (AGEN) Expected to Announce Quarterly Sales of $15.58 MillionAgenus Inc. (AGEN) Expected to Announce Quarterly Sales of $15.58 Million
www.americanbankingnews.com - December 5 at 9:06 AM

SEC Filings

Agenus (NASDAQ:AGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Agenus (NASDAQ:AGEN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Agenus (NASDAQ AGEN) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.